Active ingredientAbrocitinibCat. No. P-A007-001CAS 1622902-68-4Family · Pharmaceutical analytical standards
Abrocitinib
A selective oral Janus kinase 1 (JAK1) inhibitor, approved in 2021 in the United Kingdom, Japan and Europe and in 2022 in the United States for moderate to severe atopic dermatitis. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Its molecule joins three quite distinct parts: a pyrrolopyrimidine core, a small cyclobutane ring with just four carbon atoms, and a propanesulfonamide group.
Go to the active ingredient →Active ingredientAbrocitinibCat. No. P-A007-001CAS 1622902-68-4
Isotopically labelledAbrocitinib Impurity 11-d4Cat. No. P-A007-002
Isotopically labelledAbrocitinib Impurity 12-d4Cat. No. P-A007-003
Isotopically labelledAbrocitinib Impurity 8-d4Cat. No. P-A007-004
Isotopically labelledAbrocitinib-d7Cat. No. P-A007-005
Isotopically labelledAbrocitinib-d8Cat. No. P-A007-006
NitrosamineN1-Nitroso AbrocitinibCat. No. P-A007-007
NitrosamineN2-Nitroso AbrocitinibCat. No. P-A007-008
NitrosamineN-Nitroso N-Desmethyl AbrocitinibCat. No. P-A007-009
ImpurityAbrocitinib Impurity 1 DihydrobromideCat. No. P-A007-010CAS 1622903-42-7
ImpurityAbrocitinib Impurity 2Cat. No. P-A007-011CAS 2204280-33-9
ImpurityAbrocitinib Impurity 3Cat. No. P-A007-012
ImpurityAbrocitinib Impurity 4Cat. No. P-A007-013CAS 2744171-52-4
ImpurityAbrocitinib Impurity 5Cat. No. P-A007-014CAS 2744171-53-5
ImpurityAbrocitinib Impurity 6Cat. No. P-A007-015
ImpurityAbrocitinib Impurity 7 DihydrobromideCat. No. P-A007-016
ImpurityAbrocitinib Impurity 8Cat. No. P-A007-017
ImpurityAbrocitinib Impurity 9Cat. No. P-A007-018CAS 2204275-76-1
ImpurityHydroxy AbrocitinibCat. No. P-A007-019CAS 2744171-54-6
ImpurityAbrocitinib Impurity 10 HydrochlorideCat. No. P-A007-020CAS 2204290-99-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.